EC Number   |
General Information |
Reference |
|---|
   1.1.1.62 | drug target |
inhibition of 17beta-HSD7 constitutes the basis of breast cancer cell proliferation |
761756 |
| 1.1.1.62 | drug target |
inhibition of 17beta-hydroxysteroid dehydrogenases 1 is proposed to be a prime candidate for inhibition in patients who develop aromatase inhibitor resistance or in combination with aromatase inhibitors as a first line treatment |
762074 |
| 1.1.1.62 | drug target |
inhibition of 17beta-hydroxysteroid dehydrogenases 1 may be a prime candidate for inhibition in patients with breast cancer who develop aromatase inhibitor resistance or in combination with aromatase inhibitors as a first line treatment |
762074 |
| 1.1.1.62 | drug target |
possible role in Alzheimer's disease, inhibition appears to be a therapeutic strategy |
761037 |
| 1.1.1.62 | drug target |
the ratio of HSD17B1 to HSD17B2 is a good indicator of tamoxifen treatment benefit, as post-menopausal patients with tumors expressing a high HSD17B1/HSD17B2 protein ratio have less benefit from tamoxifen treatment |
762074 |
| 1.1.1.62 | evolution |
17beta-Hsd 14 from Euphyllia ancora clusters with other animal 17beta-HSD 14s but not with other members of the 17beta-HSD family |
740502 |
| 1.1.1.62 | evolution |
17beta-HSD1 belongs to the short-chain dehydrogenase/reductase (SDR) family and contains the conserved Rossmann-fold for nucleotide binding, the catalytic triad with residues Ser142, Tyr155, and Lys159 and a dimerization region. Residue Cys10 is highly conserved among species, including rodents and zebrafish, suggesting a role for this residue in the stability and/or function of the protein. The cysteine residue at this position is conserved in all members of the SDR9C family, except for 17beta-HSD2, which has a cysteine residue downstream by two positions |
740542 |
| 1.1.1.62 | evolution |
HSD17B12 is a member of the hydroxysteroid dehydrogenase superfamily, a multifunctional group of enzymes involved in the metabolism of steroids, retinoids, bile and fatty acids |
725829 |
| 1.1.1.62 | malfunction |
enzyme inhibition can lead to desired increase of estradiol and testosterone levels in the bone tissue and may be used for the treatment of osteoporosis |
741242 |
| 1.1.1.62 | malfunction |
estrone treatment in 17betaHSD1 positive NSCLC cells, A-549 and LK-87, results in estradiol production and enhances cell proliferation, which is abrogated effectively by 17betaHSD1 siRNA knockdown |
740924 |
